@article{22dd87d815c2470099866778d079f2e1,
title = "Reply to: {\textquoteleft}Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.{\textquoteright} by D. Fabrizio et al.",
author = "McGrail, {D. J.} and Pili{\'e}, {P. G.} and Rashid, {N. U.} and L. Voorwerk and M. Slagter and M. Kok and E. Jonasch and M. Khasraw and Heimberger, {A. B.} and Ueno, {N. T.} and R. Ferrarotto and Chang, {J. T.} and Lin, {S. Y.}",
note = "Funding Information: This work was supported by the National Cancer Institute at the National Institutes of Health [grant number K99CA240689] and Susan G. Komen [grant number PDF17483544] to DJM. MKh has served as a consultant or advisory roles for Janssen, AbbVie, Ipsen, Pfizer, Roche and Jackson Laboratory for Genomic Medicine and received research funding from AbbVie, Bristol Myers Squibb (BMS) and Specialized Therapeutics. ABH has stock options and is an advisory board member of Caris Life Sciences, serves on the advisory board of WCG Oncology, has received licensing fees from Celldex Therapeutics and DNAtrix and received research funding from Merck. MKo has advisory roles for BMS, Roche, Merck Sharp & Dohme (MSD) and Daiichi Sankyo, and the institute receives research funding from AstraZeneca, BMS and Roche outside the submitted work. DJM, PGP, EJ and SYL have a pending patent on a gene expression signature to predict response to immune checkpoint blockade. All other authors have declared no conflicts of interest. Funding Information: This work was supported by the National Cancer Institute at the National Institutes of Health [grant number K99CA240689 ] and Susan G. Komen [grant number PDF17483544 ] to DJM. ",
year = "2021",
month = sep,
doi = "10.1016/j.annonc.2021.06.017",
language = "English (US)",
volume = "32",
pages = "1194--1197",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",
}
